2nd Quarter - Report

ARENTFOX SCHIFF LLP for ORGANOGENESIS INC.

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing product

LobbyistCovered position, as disclosed
DAN RENBERG —

Health Issues HCR

Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S. 4348 (FDASLA Act of 2022), regarding Food and Drug Administration policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding Food and Drug Administration policy on chronic wound healing products

LobbyistCovered position, as disclosed
DAN RENBERG —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6000 (117th), S. 4348 (117th), H.R. 7667 (117th)

Defense DEF

Department of Defense research and development funding regarding regenerative medicine products

LobbyistCovered position, as disclosed
DAN RENBERG —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.